Jessica L. Davis
Research Interests
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Articles (8)
Year:
2026
Year:
2026
Year:
2026
Aims Rhabdomyosarcoma (RMS) is rare, but it is the most common sarcoma in childhood. The World Health Organisation classifies RMS into four main categories, sharing the same terminology of RMS, but the subtypes have different morphology, clinical behaviour and underlying molecular characterisation. Although the main diagnostic categories have remained the same there have been changes in the histological criteria, together with integration of both immunohistochemical and molecular data in the reporting of RMS. Integrated histology reporting provides valuable information for the management of children with RMS, is important for patients enrolled into clinical trials, supports tissue‐based biological research and contributes to data required in cancer registries. Consistent, comprehensive and reproducible reporting of RMS is imperative. Methods and results In this article we provide the International Collaboration on Cancer Reporting (ICCR) process for the development of the first international Paediatric RMS data set for the reporting of biopsy and resection specimens. An international expert panel consisting of pathologists and paediatric oncologists produced a set of core and non‐core elements to be included in the histopathology reporting of paediatric RMS, inclusive of clinical, macroscopic, microscopic and ancillary testing required for a comprehensive report. The selection of data items was based on review of current evidence, taking into account items that are recognised as essential for patient treatment stratification and that are currently in use in the clinical trial setting. Commentary was provided for each data item to detail the rationale for selecting it as core or non‐core element, and to highlight their clinical relevance. Conclusions The first international data set for the reporting of paediatric RMS aims to promote standardised, high‐quality reporting and supports uniform data collection, which is critical for clinical data comparison on a global level, ultimately improving patient outcome.
Year:
2025
Year:
2025
Year:
2025
Purpose: Doxorubicin is the first-line treatment for metastatic soft-tissue sarcomas. Ribociclib, a cyclin-dependent kinase 4/6 intargets the retinoblastoma pathway to induce cell-cycle arrest at the G 1 –S cell-cycle checkpoint. We hypothesized that administering ribociclib prior to doxorubicin to synchronize cell-cycle progression among tumor cells may enhance the efficacy of doxorubicin. Patients and Methods: Doxorubicin-naïve patients with metastatic soft-tissue sarcoma were enrolled in this phase Ib study. Every 21 days, subjects received ribociclib daily for 7 days followed by 3 days of no treatment before administration of doxorubicin. The primary objective was to establish the recommended phase II dose of the sequenced drug combination. Secondary objectives included progression-free survival and objective response rate. Exploratory correlative studies assessed pharmacokinetic and pharmacodynamic measures. Results: Of 38 screened patients, 16 were enrolled and 15 were evaluable for dose determination. The most common reason for exclusion was lack of normal retinoblastoma protein expression. At dose level 0 (ribociclib 400 mg and doxorubicin 75 mg/m 2 ), four of seven patients experienced febrile neutropenia as a dose-limiting toxicity. Of the eight patients treated at dose level −1 (ribociclib 400 mg and doxorubicin 60 mg/m 2 ), one had a dose-limiting toxicity of grade 4 anemia. Three patients achieved partial response (objective response rate, 20.0%). Ribociclib pharmacokinetic levels were lower than predicted. Levels of phosphorylated retinoblastoma protein in on-treatment tumor biopsy tissue were variable and did not correlate with ribociclib plasma levels. Conclusions: The recommended phase II dose is ribociclib 400 mg followed by doxorubicin 60 mg/m 2 , which demonstrated an acceptable toxicity profile.
Year:
2025
Year:
2023
Collaborators (17)
Gordon Mills
Professor
Oregon Health & Science University
Raya Saab
Stanford University
Alice Soragni
University of California
Ajay Gupta
Assistant Professor
Roswell Park Comprehensive Cancer Center
Lara Davis
Fred Hutch Cancer Center
Kelly M. Bailey
Associate Professor, Director AYA Translational Oncology
Mayo Clinic
Miguel Reyes-Mugica
Clinical Professor of Pathology. Division Director of Pediatric and Developmental Pathology
University of Miami Miller School of Medicine
Emile Latour
Oregon Health & Science University
Sapna Oberoi
Associate Professor
University of Manitoba
Sarah Dry
David Geffen School of Medicine at UCLA
David Douglass
Associate Professor
University of Arkansas for Medical Sciences
Sintawat Wangsiricharoen
Assistant Professor
Oregon Health & Science University
Susan M. Hiniker
Stanford University
Michael Michal
-
Go Nishikawa
University of Minnesota Twin Cities
Skye C. Mayo
-
Monika Davare
Oregon Health & Science University
Make your next move.
Prepare your application
Review drafts before you send them.